Cybin Inc. (CYBN)
NYSEAMERICAN: CYBN · Real-Time Price · USD
5.98
-0.09 (-1.48%)
Nov 7, 2025, 4:00 PM EST - Market closed
Cybin Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
50
Market Cap
165.20M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | - | - | - |
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | - | - | - |
| Mar 31, 2022 | - | - | - |
| Mar 31, 2021 | 686.88K | - | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CYBN News
- 2 days ago - Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025 - Business Wire
- 3 days ago - Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - Business Wire
- 5 days ago - Cybin to Participate at the 2025 Milken Institute Future of Health Summit - Business Wire
- 7 days ago - Cybin Announces Closing of $175 Million Registered Direct Offering - Business Wire
- 11 days ago - Cybin Announces $175 Million Registered Direct Offering - Business Wire
- 18 days ago - BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor - TheNewswire
- 6 weeks ago - Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones - Business Wire
- 2 months ago - CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm - Business Wire